Skip to main content
letter
. 2022 Aug 29;2(4):100199. doi: 10.1016/j.xops.2022.100199

Figure 1.

Figure 1

(A) Aflibercept prefilled syringe (PFS), (B) ranibizumab PFS, and a (H) 1 ml tuberculin (TB) barrel, and (B, E, H) with syringe stoppers fully depressed with minimal force. Each syringe had force applied by hand and the syringe stoppers can be seen deforming (red arrows C, F, and I) into the syringe barrel, decreasing the dead space in the distal aspect of the syringe. Of note, the stoppers in the aflibercept and ranibizumab PFS have a void (red arrowheads) in comparison to the TB stopper which has no void (asterisk).